Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6236169 | 0.86 | ADORA1 (0.47) | MEN1ALDH1A1KMT2AL3MBTL1MAPT | |
| SCHEMBL7026138 | 0.83 | AS3MT (0.54) | CYP1A2CYP2C19L3MBTL1GSTP1GRM2 | |
| SCHEMBL18269174 | 0.82 | ADORA1 (0.35) | MEN1ALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL22283897 | 0.82 | ADORA1 (0.51) | MEN1ALDH1A1KMT2ACYP1A2NPC1 | |
| SCHEMBL25714787 | 0.79 | KDM4E (0.37) | MEN1ALDH1A1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL28301867 | 0.77 | ERBB2 (0.43) | MEN1ALDH1A1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL3783457 | 0.76 | KDM4E (0.48) | MEN1ALDH1A1KMT2AL3MBTL1MAPT | |
| SCHEMBL15214839 | 0.76 | NPSR1 (0.33) | MEN1ALDH1A1KMT2AL3MBTL1MAPT | |
| SCHEMBL1905542 | 0.76 | ADORA1 (0.46) | MEN1ALDH1A1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL27423329 | 0.76 | ADORA1 (0.46) | MEN1ALDH1A1KMT2AMAPTADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213106-A1 | Inhibitors of Bruton's Tyrosine Kinase | PHARMACYCLICS LLC (US) | 2022-07-07 | — | — | US | disclosed |
| US-20200289515-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20200276199-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2020-09-03 | — | — | US | disclosed |
| US-20200055859-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2020-02-20 | — | — | US | disclosed |
| US-10435409-B2 | Process for the preparation of ibrutinib | SHILPA MEDICARE LIMITED | 2019-10-08 | — | — | US | disclosed |
| US-20190040069-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | SHILPA MEDICARE LIMITED (IN) | 2019-02-07 | — | — | US | disclosed |
| US-20180193345-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2018-07-12 | — | — | US | disclosed |
| EP-3311818-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | Pharmacyclics, LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9926299-B2 | Inhibitors of bruton's tyrosine kinase | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2018-03-27 | — | — | US | disclosed |
| US-20170362246-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2017-12-21 | — | — | US | disclosed |
| US-20110008257-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100331350-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100324050-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. A DELAWARE CORPORATION (US) | 2010-12-23 | — | — | US | disclosed |
| US-7825118-B2 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2010-10-07 | — | — | US | disclosed |
| US-7732454-B2 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| WO-2010009342-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2008121742-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362246-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | MEN1 3613/4885ALDH1A1 4117/4885KMT2A 890/4885 |
| US-20220213106-A1 | Inhibitors of Bruton's Tyrosine Kinase | ABL1, BTK, ABL2 | MEN1 3613/4885ALDH1A1 4117/4885KMT2A 890/4885 |
| US-20180193345-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | MEN1 2563/4885ALDH1A1 4521/4885KMT2A 501/4885 |
| US-20190040069-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | BTK, SYK, JAK1 | MEN1 2759/4885ALDH1A1 594/4885KMT2A 1120/4885 |
| US-20100324050-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | MEN1 3804/4885ALDH1A1 4459/4885KMT2A 1124/4885 |
| US-20200289515-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | MEN1 2563/4885ALDH1A1 4521/4885KMT2A 501/4885 |
| US-20100331350-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | MEN1 3804/4885ALDH1A1 4459/4885KMT2A 1124/4885 |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | MEN1 3613/4885ALDH1A1 4117/4885KMT2A 890/4885 |
| US-20110008257-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | MEN1 3804/4885ALDH1A1 4459/4885KMT2A 1124/4885 |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | BTK, LCK, LYN | MEN1 4689/4885ALDH1A1 3498/4885KMT2A 1278/4885 |
| US-20200055859-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | ABL1, BTK, ABL2 | MEN1 3479/4885ALDH1A1 4019/4885KMT2A 781/4885 |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | BTK, LCK, LYN | MEN1 4709/4885ALDH1A1 3500/4885KMT2A 1393/4885 |
| US-20200276199-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | MEN1 2563/4885ALDH1A1 4521/4885KMT2A 501/4885 |
| US-10435409-B2 | Process for the preparation of ibrutinib | BTK, SYK, JAK1 | MEN1 2668/4885ALDH1A1 534/4885KMT2A 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.